Diminished ovarian reserve
Conditions
Interventions
Experimental Group:DJP-11 Herbal Formula
Sponsors
The First Affiliated Hospital of Guangzhou University of Chinese, Guangzhou
Eligibility
Sex/Gender
Female
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: 1. Subjects aged between 18 and 45 years; 2. Meeting the Western medical diagnostic criteria for DOR (Diminished Ovarian Reserve); 3. Meeting the TCM (Traditional Chinese Medicine) syndrome differentiation of Kidney Deficiency and Liver Depression Pattern (1) soreness and weakness of the waist and knees; 2) dizziness and tinnitus; 3) nocturia/polyuria at night; 4) decreased libido; 5) emotional depression or irritability; 6) breast distension and pain; 7) chest tightness or lower abdominal pain; dark tongue with thin yellow coating, wiry-thin or deep-wiry pulse. At least one item from 1) to 4) and one item from 5) to 7) as secondary symptoms, combined with tongue and pulse findings for syndrome differentiation); 4. Having no pregnancy intention within the past 6 menstrual cycles; 5. Voluntarily participating and signing the written informed consent form; 6. Willingly accepting all follow-up evaluations required by the treatment protocol.
Exclusion criteria
Exclusion criteria: 1. Those with congenital abnormalities of the reproductive organs, or primary or secondary amenorrhea caused by acquired organic lesions or injuries; 2. Those with severe primary diseases of the cardiovascular, hepatic, renal, and hematopoietic systems, diabetic patients, and psychiatric patients; 3. Those who have undergone bilateral or unilateral oophorectomy; 4. Those with known or suspected breast cancer, known or suspected hormone-dependent precancerous lesions or malignant tumors; 5. Those who have used hormones within the past 2 months; 6. Those with known hypersensitivity to any component of this medication; 7. Those with severe hypertriglyceridemia; 8. Pregnant and lactating women; 9. Subjects whom the investigator deems to have poor compliance, inability to assess efficacy, or incomplete data that may affect efficacy evaluation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Level of baseline follicle-stimulating hormone;Level of baseline anti-Müllerian hormone; | — |
Secondary
| Measure | Time frame |
|---|---|
| Antral Follicle Count; Luteinizing Hormone;estradiol;Traditional Chinese Medicine (TCM) Symptom Score;Evaluation of Menstrual Regulation Therapeutic Effect; | — |
Countries
China
Contacts
Public ContactJie Gao
The First Affiliated Hospital of Guangzhou University of Chinese, Guangzhou
Outcome results
None listed